After more than 5 years of follow-up, women who received a gonadotropin-releasing hormone agonist (GnRHa) did not have higher rates of ovarian reserve or pregnancy, as compared with women who received chemotherapy without the GnRHa. Premature ovarian failure had significant associations with patient age, the conditioning regimen for hemopoietic stem cell transplant, and cumulative dose of cyclophosphamide but not the use of a GnRHa, as reported online in the Journal of Clinical Oncology.
No Ovarian Protection in Cancer With GnRH Agonist(2)
